Scaling an injectable from pilot to commercial at a CMO is rarely blocked by formulation alone. A lot of “surprises” happen at the last meters of the line: stopper placement, cap feeding, crimping, inspection, and container closure integrity (CCI).
For a Tech Transfer Manager, the goal is simple: deliver a closure setup that runs the same way on different capper models, different shifts, different sites, with a data package that QA can defend.
One reminder before diving in: EMA Pharma manufactures aluminum overseals (crimp caps, flip-off, tear-off, push-off). Rubber stoppers are a different supply stream and touch the drug; overseals do not. Still, the overseal and the capping process can make or break CCI, so they belong in your tech transfer scope.
A cap that “works in R&D” can fail at the CMO for three repeatable reasons:
EU GMP Annex 1 is explicit: if capping is performed outside the aseptic processing area, stoppered vials should be protected with a Grade A air supply until the cap has been crimped (with background at least Grade D). It also calls out stopper-height detection when capping is done as a clean process with Grade A air supply.
That drives immediate component choices:
USP’s package integrity chapter frames CCI as a structured program for sterile products and container-closure systems.
If your tech transfer package still relies on a single probabilistic method, expect questions during PPQ, site validation, or audits.
Different cappers, tooling wear, and line speeds change how the stopper is compressed under the cap. Scale-up gets easier when you define:
That’s where Residual Seal Force (RSF) becomes a strong bridge metric.
Think of cap format as a cleanroom logistics decision as much as a product decision.
RTS caps are intended to enter controlled environments and go through steam sterilization at the site.
Use RTS when:
EMA Pharma describes RTU caps as cleaned to low particle/bioburden levels, double-packed in heat-sealed PE bags, then sterilized by ionizing radiation in final packaging, with a validated process and shelf-life stated as more than 3 years.
RTU fits well when:
EMA Pharma lists RTP (Rapid Transfer Port) bags for direct introduction to isolators as an available packaging format.
Choose this early if the receiving CMO is isolator-first, because it impacts:
Your cap must match vial standards used at the CMO (common sizes include 13 mm, 20 mm, 32 mm, etc.). EMA’s crimp cap guide references these standard neck sizes and typical aluminum shell construction.
EMA’s aluminum cap range includes:
Tech transfer tip: opening force and user steps matter more at commercial scale than teams expect. If your program includes hospital handling, clinical sites, or patient-facing use, choose the access concept before PPQ so you don’t re-validate downstream.
For aluminum caps and aluminum/plastic caps used on infusion bottles and injection vials, ISO references include:
Even if an overseal does not contact the drug, your quality narrative improves when your supplier can map product specs and controls to these references.
PDA training material defines RSF as the force a compressed elastomeric stopper flange continues to exert on the vial sealing surface after crimping and positions it as a quantitative way to standardize seal quality regardless of capping equipment.
Two practical rules for tech transfer:
Annex 1 states that when capping is a clean process under Grade A air supply protection, vials with missing or displaced stoppers should be rejected prior to capping, and automated methods for stopper-height detection should be in place.
For tech transfer, that means:
(Useful industry discussion exists on correlating stopper height to CCI risk, including vendor guidance that explicitly references Annex 1 §8.28.)
Annex 1 flags that crimping equipment can generate large quantities of non-viable particles and calls for measures like physical separation and adequate extraction.
If your CMO struggles with particle excursions, cap choice alone won’t save you—your transfer package should include capper station design notes.
Here’s a checklist you can hand over as a single deliverable.
EMA’s RTU description includes double PE bagging and gamma sterilization in final packaging, which is exactly the type of process detail a CMO needs in a transfer file.
EMA’s supplier-selection blog highlights DMF filings (US and China) and points to the need for irradiation validation and certificates for RTU caps, plus change control expectations, these items fit directly into lifecycle planning.
When you evaluate or brief a supplier, ask for support in five buckets:
EMA’s service pages describe “EMA CLEAN-CAPS” and their positioning for low particulate/bioburden levels and readiness for controlled environments, which aligns with what tech transfer teams need to remove late surprises.
Does an aluminum crimp cap count as primary packaging?
The cap does not contact the drug, but it is part of the container-closure system that protects sterility and CCI. USP’s integrity chapter explicitly addresses container-closure systems for sterile products.
When should a program choose RTU caps?
When you want to remove site sterilization variability and bring a double-packed, gamma-sterilized component into the aseptic area. EMA describes RTU caps as double-packed and sterilized by ionizing radiation in final packaging with a validated process and a stated shelf life of more than 3 years.
What does Annex 1 say about capping outside the aseptic area?
Annex 1 allows capping as a clean process outside the aseptic processing area, with Grade A protection for stoppered vials via Grade A air supply until crimping, plus stopper-height detection expectations.
Is RSF enough to prove container closure integrity?
RSF is a quantitative process metric tied to stopper compression. It should be correlated with validated CCIT methods and used to keep the process in control during scale-up and routine manufacture.